Watts R W, Danpure C J, De Pauw L
Royal Postgraduate Medical School, Hammersmith, Hospital, London, UK.
Nephrol Dial Transplant. 1991;6(7):502-11. doi: 10.1093/ndt/6.7.502.
The data provided by 14 European centres concerning 22 combined liver-kidney and two isolated liver grafts performed in primary hyperoxaluria type 1 (PH1) were discussed at a workshop which drew the following main conclusions: 1. In end-stage renal failure due to PH1 1-year kidney graft survival rate is far better after combined liver-kidney transplantation than after kidney transplantation alone. This may be due to enhanced renal graft tolerance induced by the simultaneously grafted liver, in addition to the reduced risk of oxalate-induced damage to the kidney graft because the oxalate overproduction has been corrected. 2. Prolonged dialysis using conventional regimes gives rise to extensive systemic oxalosis, especially oxalate osteopathy, which leads to long-lasting excretion of large amounts of oxalate even after oxalate synthesis has been normalised by liver-kidney transplantation, with the risk of jeopardising the success of the kidney graft. In addition, oxalate arteriopathy may endanger the recipient's life. 3. Patients whose GFR is in the range of 25-60 ml/min per 1.73 m2 should be followed up closely, with sequential assessments based on the rate of loss of overall renal function and the plasma and urine oxalate values. An isolated liver transplantation should be considered once the disease has been shown to be following an aggressive course. If this strategy is not followed, planning for an elective liver-kidney graft should begin when GFR decreases to about 25 ml/min per 1.73 m2 and the operation should be as soon as possible. 4. As orthotopic liver transplantation involves the removal of the recipient's biochemically defective but otherwise normal liver, the diagnosis of PH1 should be unequivocally established in every case by the measurement of alanine: glyoxylate aminotransferase enzyme activity in a preoperative liver biopsy.
14个欧洲中心提供了关于在1型原发性高草酸尿症(PH1)患者中进行的22例肝肾联合移植和2例单纯肝移植的数据。在一次研讨会上对这些数据进行了讨论,得出了以下主要结论:1. 在因PH1导致的终末期肾衰竭患者中,肝肾联合移植后的1年肾移植存活率远高于单纯肾移植。这可能是由于同时移植的肝脏增强了对肾移植的耐受性,此外,由于草酸盐过度生成已得到纠正,草酸盐诱导的肾移植损伤风险降低。2. 使用传统方案进行长期透析会导致广泛的全身性草酸沉积症,尤其是草酸骨病,即使在肝肾移植使草酸盐合成恢复正常后,仍会导致大量草酸盐长期排泄,从而有危及肾移植成功的风险。此外,草酸动脉病可能危及受者生命。3. 肾小球滤过率(GFR)在每1.73平方米25 - 60毫升/分钟范围内的患者应密切随访,根据总体肾功能丧失率以及血浆和尿液草酸盐值进行连续评估。一旦疾病显示进展迅速,应考虑进行单纯肝移植。如果不采取这一策略,当GFR降至每1.73平方米约25毫升/分钟时,应开始计划择期肝肾移植,并且手术应尽快进行。4. 由于原位肝移植需要切除受者生化功能有缺陷但其他方面正常的肝脏,因此在每例病例中,术前肝活检应通过测量丙氨酸:乙醛酸转氨酶活性明确诊断PH1。